
Opinion|Videos|December 15, 2023
Antibody-Drug Conjugate Safety Profiles in NSCLC
Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS
Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5







































